{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T20:49:11Z","timestamp":1769201351732,"version":"3.49.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2010,2,27]],"date-time":"2010-02-27T00:00:00Z","timestamp":1267228800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Diab Rep"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1007\/s11892-010-0095-5","type":"journal-article","created":{"date-parts":[[2010,2,26]],"date-time":"2010-02-26T02:52:06Z","timestamp":1267152726000},"page":"101-107","source":"Crossref","is-referenced-by-count":21,"title":["Turning Glucosuria into a Therapy: Efficacy and Safety with SGLT2 Inhibitors"],"prefix":"10.1007","volume":"10","author":[{"given":"Anupa K.","family":"Patel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vivian","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,2,27]]},"reference":[{"key":"95_CR1","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2174\/1381612013397915","volume":"7","author":"A Wagman","year":"2001","unstructured":"Wagman A, Nuss JM: Current therapies and emerging targets for the treatment of diabetes. Curr Pharm Des 2001, 7:417\u2013450.","journal-title":"Curr Pharm Des"},{"key":"95_CR2","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1053\/j.ajkd.2008.12.031","volume":"53","author":"O Marsenic","year":"2009","unstructured":"Marsenic O: Glucose control by the kidney: an emerging target in diabetes. Am J Kidney Dis 2009, 53:875\u2013883.","journal-title":"Am J Kidney Dis"},{"key":"95_CR3","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s00424-003-1202-0","volume":"447","author":"EM Wright","year":"2004","unstructured":"Wright EM, Turk E: The sodium\/glucose cotransport family SCL5. Pflugers Arch 2004, 447:510\u2013518.","journal-title":"Pflugers Arch"},{"key":"95_CR4","doi-asserted-by":"crossref","first-page":"F10","DOI":"10.1152\/ajprenal.2001.280.1.F10","volume":"280","author":"EM Wright","year":"2001","unstructured":"Wright EM: Renal Na(+)-glucose cotransporters. Am J Physiol Renal Physiol 2001, 280:F10\u2013F18.","journal-title":"Am J Physiol Renal Physiol"},{"key":"95_CR5","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1038\/ki.2009.87","volume":"75","author":"GL Bakris","year":"2009","unstructured":"Bakris GL, Fonseca V, Sharma K, Wright EM: Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int 2009, 75:1272\u20131277.","journal-title":"Kidney Int"},{"key":"95_CR6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1079\/BJN2002763","volume":"89","author":"IS Wood","year":"2003","unstructured":"Wood IS, Trayburn P: Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins. Br J Nutr 2003, 89:3\u20139.","journal-title":"Br J Nutr"},{"key":"95_CR7","doi-asserted-by":"crossref","first-page":"131","DOI":"10.7150\/ijms.4.131","volume":"4","author":"F Castaneda","year":"2007","unstructured":"Castaneda F, Burse A, Boland W, Kinne RK: Thioglycosides as inhibitors of hSGLT1 and hSGLT2: potential therapeutic agents for the control of hyperglycemia in diabetes. Int J Med Sci 2007, 4:131\u2013139.","journal-title":"Int J Med Sci"},{"key":"95_CR8","doi-asserted-by":"crossref","first-page":"3427","DOI":"10.2337\/diabetes.54.12.3427","volume":"54","author":"H Rahmoune","year":"2005","unstructured":"Rahmoune H, Thompson PW, Ward JM, et al.: Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 2005, 54:3427\u20133434.","journal-title":"Diabetes"},{"key":"95_CR9","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1172\/JCI116972","volume":"93","author":"Y Kanai","year":"1994","unstructured":"Kanai Y, Lee WS, You G, et al.: The human kidney low affinity Na+\/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose. J Clin Invest 1994, 93:397\u2013404.","journal-title":"J Clin Invest"},{"key":"95_CR10","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1152\/physrev.1994.74.4.993","volume":"74","author":"MA Hediger","year":"1994","unstructured":"Hediger MA, Rhoads DB: Molecular physiology of sodium\u2013glucose cotransporters. Physiol Rev 1994, 74:993\u20131026.","journal-title":"Physiol Rev"},{"key":"95_CR11","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/jcb.10631","volume":"90","author":"L Zhou","year":"2003","unstructured":"Zhou L, Cryan EV, D\u2019Andrea MR, et al.: Human cardiomyocytes express high level of Na+\/glucose cotransporter 1 (SGLT1). J Cell Biochem 2003, 90:339\u2013346.","journal-title":"J Cell Biochem"},{"key":"95_CR12","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1023\/A:1018807120691","volume":"42","author":"AB Thomson","year":"1997","unstructured":"Thomson AB, Wild G: Adaptation of intestinal nutrient transport in health and disease. Part I. Dig Dis Sci 1997, 42:453\u2013469.","journal-title":"Dig Dis Sci"},{"key":"95_CR13","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1210\/en.2007-1088","volume":"149","author":"HS Freitas","year":"2008","unstructured":"Freitas HS, Anhe GF, Melo KF, et al.: Na(+)-glucose transporter-2 messenger ribonucleic acid expression in kidney of diabetic rats correlates with glycemic levels: involvement of hepatocyte nuclear factor-1alpha expression and activity. Endocrinology 2008, 149:717\u2013724.","journal-title":"Endocrinology"},{"key":"95_CR14","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1038\/sj.bjp.0703829","volume":"132","author":"K Arakawa","year":"2001","unstructured":"Arakawa K, Ishihara T, Oku A, et al.: Improved diabetic syndrome in C57BL\/KsJ-db\/db mice by oral administration of the Na(+)-glucose cotransporter inhibitor T-1095. Br J Pharmacol 2001, 132:578\u2013586.","journal-title":"Br J Pharmacol"},{"key":"95_CR15","unstructured":"NCBI: OMIM\u2013Online Mendelian Inheritance in Man. Available at http:\/\/www.ncbi.nlm.nih.gov\/omim . Accessed December 2009."},{"key":"95_CR16","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1365-2796.2006.01746.x","volume":"261","author":"EM Wright","year":"2007","unstructured":"Wright EM, Hirayama BA, Loo DF: Active sugar transport in health and disease. J Intern Med 2007, 261:32\u201343.","journal-title":"J Intern Med"},{"key":"95_CR17","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1097\/01.ASN.0000092790.89332.D2","volume":"14","author":"R Santer","year":"2003","unstructured":"Santer R, Kinner M, Lassen CL, et al.: Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol 2003, 14:2873\u20132882.","journal-title":"J Am Soc Nephrol"},{"key":"95_CR18","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1111\/j.1742-1241.2008.01829.x","volume":"62","author":"SA Jabbour","year":"2008","unstructured":"Jabbour SA, Goldstein BJ: Sodium glucose co-transporter 2 inhibitors: blocking renal tubular reabsorption of glucose to improve glycaemic control in patients with diabetes. Int J Clin Pract 2008, 62:1279\u20131284.","journal-title":"Int J Clin Pract"},{"key":"95_CR19","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/j.1463-1326.2008.00982.x","volume":"11","author":"I Idris","year":"2009","unstructured":"Idris I, Donnelly R: Sodium-glucose co-transporter-2 inhibitors: an emerging new class of oral antidiabetic drug. Diabetes Obes Metab 2009, 11:79\u201388.","journal-title":"Diabetes Obes Metab"},{"key":"95_CR20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/dmrr.532","volume":"21","author":"JR Ehrenkranz","year":"2005","unstructured":"Ehrenkranz JR, Lewis NG, Kahn CR, Roth J: Phlorizin: a review. Diabetes Metab Res Rev 2005, 21:31\u201338.","journal-title":"Diabetes Metab Res Rev"},{"key":"95_CR21","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1021\/jm701272q","volume":"51","author":"W Meng","year":"2008","unstructured":"Meng W, Ellsworth BA, Nirschl AA, et al.: Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 2008, 51:1145\u20131149.","journal-title":"J Med Chem"},{"key":"95_CR22","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1124\/jpet.106.110296","volume":"320","author":"K Katsuno","year":"2007","unstructured":"Katsuno K, Fujimori Y, Takemura Y, et al.: Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level. J Pharmacol Exp Ther 2007, 320:323\u2013330.","journal-title":"J Pharmacol Exp Ther"},{"key":"95_CR23","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1172\/JCI112981","volume":"79","author":"L Rossetti","year":"1987","unstructured":"Rossetti L, Smith D, Shulman GI, et al.: Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 1987, 79:1510\u20131515.","journal-title":"J Clin Invest"},{"key":"95_CR24","unstructured":"U.S. National Institutes of Health: Registry of ClinicalTrials.gov. Available at http:\/\/www.clinicaltrials.gov . Accessed December 2009."},{"key":"95_CR25","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1517\/13543780902766794","volume":"18","author":"M Kipnes","year":"2009","unstructured":"Kipnes M: Dapagliflozin: an emerging treatment option in type 2 diabetes. Expert Opin Investig Drugs 2009, 18:327\u2013334.","journal-title":"Expert Opin Investig Drugs"},{"key":"95_CR26","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ejphar.2009.03.007","volume":"609","author":"Y Fujimori","year":"2009","unstructured":"Fujimori Y, Katsuno K, Ojima K, et al.: Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats. Eur J Pharmacol 2009, 609:148\u2013154.","journal-title":"Eur J Pharmacol"},{"issue":"Suppl 1","key":"95_CR27","first-page":"S376","volume":"50","author":"S Ghosh","year":"2007","unstructured":"Ghosh S, Shen Y, Harrington WW, et al.: Metabolic responses to a sodium\u2013glucose transporter-2 inhibitor, GW869682, assessed by whole-genome transcript profiling. Diabetologia 2007, 50(Suppl 1):S376.","journal-title":"Diabetologia"},{"key":"95_CR28","unstructured":"DiabesityDigest.com, your online resource for obesity and type 2 diabetes. Available at http:\/\/www.diabesitydigest.com . Accessed December 2009."},{"key":"95_CR29","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1124\/jpet.108.140210","volume":"327","author":"Y Fujimori","year":"2008","unstructured":"Fujimori Y, Katsuno K, Nakashima I, et al.: Remogliflozin etabonate, in a novel category of selective low-affinity sodium glucose cotransporter (SGLT2) inhibitors, exhibits antidiabetic efficacy in rodent models. J Pharmacol Exp Ther 2008, 327:268\u2013276.","journal-title":"J Pharmacol Exp Ther"},{"key":"95_CR30","unstructured":"Kissei Pharmaceutical Co., Ltd. Available at http:\/\/www.kissei.co.jp . Accessed November 2009."},{"key":"95_CR31","unstructured":"Wancewicz EV, Siwkowski A, Meibohm B, et al.: Long-term safety and efficacy of ISIS 388626, an optimized SGLT2 antisense inhibitor, in multiple diabetic and euglycemic species. Presented at the 68th Scientific Sessions of the American Diabetes Association. San Francisco, CA; June 6\u201310, 2008."},{"key":"95_CR32","unstructured":"Bhanot S, Murray SF, Booten SL, et al.: ISIS 388626, an SGLT2 Antisense drug, causes robust and sustained glucosuria in multiple species and is safe and well tolerated. Presented at the 69th Scientific Sessions of the American Diabetes Association. New Orleans, LA; June 5\u20139, 2009."},{"key":"95_CR33","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/clpt.2008.250","volume":"85","author":"B Komoroski","year":"2009","unstructured":"\u2022 Komoroski B, Vachharajani N, Feng Y, et al.: Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther 2009, 85:513\u2013519. This paper describes a phase 3 clinical trial showing favorable results of SGLT2 inhibition on glycemic parameters.","journal-title":"Clin Pharmacol Ther"},{"key":"95_CR34","doi-asserted-by":"crossref","first-page":"650","DOI":"10.2337\/dc08-1863","volume":"32","author":"JF List","year":"2009","unstructured":"List JF, Woo V, Morales E, et al.: Sodium\u2013glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care 2009, 32:650\u2013657.","journal-title":"Diabetes Care"},{"key":"95_CR35","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.2337\/diabetes.48.9.1794","volume":"48","author":"A Oku","year":"1999","unstructured":"Oku A, Ueta K, Arakawa K, et al.: T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes 1999, 48:1794\u20131800.","journal-title":"Diabetes"},{"key":"95_CR36","doi-asserted-by":"crossref","first-page":"5311","DOI":"10.1021\/jm990175n","volume":"42","author":"K Tsujihara","year":"1999","unstructured":"Tsujihara K, Hongu M, Saito K, et. al.: Na(+)-glucose cotransporter (SGLT) inhibitors as antidiabetic agents. 4. Synthesis and pharmacological properties of 4\u2032-dehydroxyphlorizin derivatives substituted on the B ring. J Med Chem 1999, 42:5311\u20135324.","journal-title":"J Med Chem"},{"key":"95_CR37","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1053\/meta.2000.7729","volume":"49","author":"T Adachi","year":"2000","unstructured":"Adachi T, Yasuda K, Okamoto Y, et al.: T-1095, a renal Na+-glucose transporter inhibitor, improves hyperglycemia in streptozotocin-induced diabetic rats. Metabolism 2000, 49:990\u2013995.","journal-title":"Metabolism"},{"key":"95_CR38","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1016\/j.lfs.2004.09.038","volume":"76","author":"K Ueta","year":"2005","unstructured":"Ueta K, Ishihara T, Matsumoto Y, et al.: Long-term treatment with the Na+-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki Rats. Life Sci 2005, 76:2655\u20132668.","journal-title":"Life Sci"},{"key":"95_CR39","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.2337\/dc09-0517","volume":"32","author":"JP Wilding","year":"2009","unstructured":"\u2022\u2022 Wilding JP, Norwood P, T\u2019Joen C, et al.: A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care 2009, 32:1656\u20131662. This paper describes a phase 3 clinical trial in which SGLT2 inhibitor use with insulin and oral antidiabetic agents showed improvement in glycemic parameters alone with promising data on weight loss.","journal-title":"Diabetes Care"},{"key":"95_CR40","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.2337\/diacare.23.12.1737","volume":"23","author":"SE Geerlings","year":"2000","unstructured":"Geerlings SE, Stolk RP, Camps MJ, et al.: Risk factors for symptomatic urinary tract infection in women with diabetes. Diabetes Care 2000, 23:1737\u20131741.","journal-title":"Diabetes Care"}],"container-title":["Current Diabetes Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-010-0095-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11892-010-0095-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11892-010-0095-5","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T23:56:22Z","timestamp":1559433382000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11892-010-0095-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,27]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["95"],"URL":"https:\/\/doi.org\/10.1007\/s11892-010-0095-5","relation":{},"ISSN":["1534-4827","1539-0829"],"issn-type":[{"value":"1534-4827","type":"print"},{"value":"1539-0829","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2,27]]}}}